Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896989 | 0.91 | ELANE (0.80) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL14899948 | 0.89 | ELANE (0.77) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL395509 | 0.88 | ELANE (0.83) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL393399 | 0.88 | ELANE (0.83) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL7905406 | 0.88 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL10013429 | 0.88 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-678 SCHEMBL1245235 | 0.85 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245423 | 0.85 | ELANE (0.87) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-678 SCHEMBL1245297 | 0.85 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-677 SCHEMBL4179543 | 0.85 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER IP GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-1730121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER IP GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8343987-B2 | Heterocyclic derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343987-B2 | Heterocyclic derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-01 | — | — | US | disclosed |
| US-7893073-B2 | Heterocyclic derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-22 | — | — | US | disclosed |
| US-7893073-B2 | Heterocyclic derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-22 | — | — | US | disclosed |
| US-7893073-B2 | Heterocyclic derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-22 | — | — | US | disclosed |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
| WO-2005082863-A2 | 1,4 DIARYL-DIHYDROPYRIMIDIN-2 ONES AND THEIR USE AS A HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021053-A1 | Heterocyclic Derivatives | TNNI3, CYP11B2, TNNT2 | ELANE 132/4885CYP2C9 838/4885ADRB1 72/4885 |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | TNNI3, TNNT2, CYP11B2 | ELANE 132/4885CYP2C9 854/4885ADRB1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.